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What does the future hold 
for Cardiology? 
Are we the disruptors or disruptee’s?
EDITORIAL
It’s been a great privilege and honour to be the Chairman of the SA Heart® Congress 2018 scientific 
committee. It has been a road with some challenges, but I mostly have admiration for my fellow 
committee members and the SA Heart® Exco who all played a valuable role. The focus has been on 
what does the future hold in cardiology? 
Will we be able to repair most valvular diseases percutaneously in the next decade? 
The aortic valve, once the sacred domain of the cardiac surgeon, has succumbed to innovation intro-
duced by the interventional cardiologist. Transcatheter aortic valve replacement (TAVR) for the aortic 
valve, initially introduced as a percutaneous therapeutic option for high-risk inoperable patients, has 
now become the domain of the heart team, where cardiologist and cardiac surgeon work side by 
side, offering this as a routine procedure for intermediate (and possibly soon even in low-risk patients), 
in most large centres. The dream of 10 years ago has become the reality of today.
Will the mitral valve be next? 
The mitra-clip is already in clinical use, and may prove to be beneficial in some patients. However, the 
mitral valve is more complex, and we will in all likelihood require several variants and options going 
forward to tackle the various pathologies. The challenge to include an annuloplasty in a percutaneous 
approach to mitral valve repair (an integral component of surgical valve repair strategies), has not yet 
been overcome successfully. Valve-in-valve percutaneous mitral valve replacement is already a reality, 
but the race to develop a percutaneous valve that can be deployed in the mitral position in patients 
who have not undergone previous mitral valve surgery is still on.
The intervention vs. medical therapy vs. surgery debate for the management of stable coronary artery 
disease still continues. The Orbita data, which is a multicentre randomised trial of PCI versus placebo 
for angina relief that was performed at 5 sites in the UK, concluded that in stable angina with severe 
coronary stenosis PCI did not increase exercise time by more than the effect of the placebo proce-
dure at 6 weeks. The great stable angina debate will highlight all the controversies of this study and 
others at SAHA 2018.
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Will medical therapy replace all forms of intervention in the future?
The Glagov study showed plaque reduction as measured by IVUS in patients receiving PCSK9 
inhibitors – is this the beginning of plaque reduction via medical therapy?
How would the LDL receptor disruptors like inclisiran play a role, especially with their need to 
be only administered 6-monthly? Certainly, better compliance, lower LDLs, less plaque burden 
and maybe … plaque regression? Only the future will tell.
How will big data disrupt the way we currently practise?
Artificial intelligence is already replacing lawyers, especially for contract work, and how will the 
cardiologist be affected? ECG interpretation is already at a stage where, in most cases, the 
Artificial intelligence programme would correctly interpret the ECG and give a differential diag-
nosis. Hence, this lowers the chances of missing a critical diagnosis like STEMIs and shorter door 
to balloon times.
Robotics are already in daily use for electrophysiological studies (EP) and ablations, with virtual 
reality playing an important role – especially as demonstrated in paediatric ablations and EP 
studies. The next step would be MRI-guided interventional catheters that are robotically guided, 
so obviating the use of x-rays and increasing the accuracy and predictability of interventional 
cardiology.
Is the eradication of cardiovascular disease a possibility in the future – especially in the era of 
vaccines, early detection, preventative medicine, better predictive models using big data 
analytics, robotics, artificial intelligence and virtual reality? 
Or should we rather be asking: How will we use the new disruptive technologies to deliver a 
better healthcare system for everyone in a just and equitable manner?
